Uncomplicated Falciparum Malaria Clinical Trial
Official title:
An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria
Verified date | November 2015 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | Myanmar: Ethical Review Committee |
Study type | Interventional |
Emerging resistance to artemisinins and their partner drugs severely threatens the treatment
of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug
policy, it is crucial to evaluate alternative antimalarial treatments.
The investigators here propose a randomized clinical trial comparing parasite clearance
parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days
dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria
in Myanmar stratified for the presence of "K13" mutation in the infecting parasite strains.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female aged = 18 year old - Symptomatic malaria infection, i.e. history of fever or presence of fever >37.5°c (tympanic) within the last 24 hours. - Microscopic confirmation of asexual stages of P.falciparum (may be mixed with non-falciparum species) with a parasitaemia >10,000 parasites/µL - Able to take oral medication - Willingness and ability of patients to comply with the study protocol for the duration of the study - Written informed consent given to participate in the trial Exclusion Criteria: - Pregnancy or lactation (urine test for ß HCG to be performed on any woman of child bearing age 18 to 45 year old) - P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL). - Signs or symptoms indicative of severe malaria: - Impaired consciousness - Severe anaemia (Hct<15%) - Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venipuncture sites - Respiratory distress - Severe jaundice - Have taken a full course DHA-piperaquine, artemether-lumefantrin or other antimalarial treatment in the previous 42 days - Known hypersensitivity to artemisinins or to piperaquine - defined as history of erythroderma/other severe cutaneous reaction or angioedema - History of splenectomy - History of taking medicinal products that are known to prolong the QTc interval, including: - Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol). - Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents. - Certain antimicrobial agents, including agents of the following classes: - macrolides (e.g. erythromycin, clarithromycin), - fluoroquinolones (e.g. moxifloxacin, sparfloxacin), - imidazole and triazole antifungal agent, - pentamidine and saquinavir. - The non-sedating antihistamines terfenadine, astemizole, mizolastine. - Other drugs: cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide. - History of taking any drug which is known to be metabolised by the cytochrome enzyme CYP2D6 including flecainide, metoprol, imipramine, amitriptyline, clomipramine. - Family history of sudden unexplained death, or personal or family history of predisposing cardiac conditions for arrhythmia/QT prolongation (including congenital long QT syndrome, arrhythmia, QTc interval greater than 450 milliseconds with either Bazett or Fridericia correction). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | Department of Medical Research, Lower Myanmar, Mahidol Oxford Tropical Medicine Research Unit |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peripheral blood parasite half-life | Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion >10,000 parasites/µL | 2 years | Yes |
Secondary | 42 day PCR corrected adequate clinical and parasitological response (ACPR) | 42 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00936767 -
Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04009343 -
Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials
|
Phase 2/Phase 3 | |
Completed |
NCT00682578 -
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
|
Phase 3 | |
Completed |
NCT00959517 -
Trial of Artesunate Combination Therapy in Pakistan
|
Phase 2 | |
Completed |
NCT03431714 -
Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania
|
Phase 4 | |
Recruiting |
NCT00902811 -
Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria
|
Phase 4 | |
Completed |
NCT01407887 -
Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children
|
Phase 2 | |
Completed |
NCT00356005 -
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
|
Phase 2 |